| Sulfoximines: a neglected opportunity in medicinal chemistry U Lücking Angewandte Chemie International Edition 52 (36), 9399-9408, 2013 | 523 | 2013 |
| Tuning glycoside reactivity: New tool for efficient oligosaccharide synthesis NL Douglas, SV Ley, U Lücking, SL Warriner Journal of the Chemical Society, Perkin Transactions 1, 51-66, 1998 | 335 | 1998 |
| Neglected sulfur (VI) pharmacophores in drug discovery: exploration of novel chemical space by the interplay of drug design and method development U Lücking Organic Chemistry Frontiers 6 (8), 1319-1324, 2019 | 217 | 2019 |
| Novel pieces for the emerging picture of sulfoximines in drug discovery: synthesis and evaluation of sulfoximine analogues of marketed drugs and advanced clinical candidates JA Sirvent, U Lücking ChemMedChem 12 (7), 487-501, 2017 | 167 | 2017 |
| The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R,2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2 … U Lücking, R Jautelat, M Krüger, T Brumby, P Lienau, M Schäfer, H Briem, ... ChemMedChem 8 (7), 1067-1085, 2013 | 167 | 2013 |
| BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono-and in combination treatment upon oral application G Siemeister, U Lücking, AM Wengner, P Lienau, W Steinke, C Schatz, ... Molecular cancer therapeutics 11 (10), 2265-2273, 2012 | 159 | 2012 |
| The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical cancer models AM Wengner, G Siemeister, U Lücking, J Lefranc, L Wortmann, P Lienau, ... Molecular cancer therapeutics 19 (1), 26-38, 2020 | 155 | 2020 |
| Progress towards a public chemogenomic set for protein kinases and a call for contributions DH Drewry, CI Wells, DM Andrews, R Angell, H Al-Ali, AD Axtman, ... PloS one 12 (8), e0181585, 2017 | 151 | 2017 |
| Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer U Lücking, A Scholz, P Lienau, G Siemeister, D Kosemund, R Bohlmann, ... ChemMedChem 12 (21), 1776-1793, 2017 | 140 | 2017 |
| Compound and a composition including such a compound T Brumby, R Jautelat, O Prien, M Schäfer, G Siemeister, U Lücking, ... US Patent 7,235,561, 2007 | 128 | 2007 |
| Straightforward strategies for the preparation of NH-sulfoximines: a serendipitous story JA Bull, L Degennaro, R Luisi Synlett 28 (19), 2525-2538, 2017 | 122 | 2017 |
| Rapid Assembly of Oligosaccharides: Total Synthesis of a Glycosylphosphatidylinositol Anchor of Trypanosoma brucei DK Baeschlin, AR Chaperon, V Charbonneau, LG Green, SV Ley, ... Angewandte Chemie International Edition 37 (24), 3423-3428, 1998 | 118 | 1998 |
| From the insoluble dye indirubin towards highly active, soluble CDK2‐inhibitors R Jautelat, T Brumby, M Schäfer, H Briem, G Eisenbrand, S Schwahn, ... ChemBioChem 6 (3), 531-540, 2005 | 113 | 2005 |
| Sulfoximine: Eine vernachlässigte Chance in der medizinischen Chemie U Lücking Angewandte Chemie 125 (36), 9570-9580, 2013 | 102 | 2013 |
| Macrocyclic pyrimidines, their production and use as pharmaceutical agents U Luecking, G Siemeister, M Schaefer, H Briem US Patent 7,312,225, 2007 | 97 | 2007 |
| Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents U Luecking, G Siemeister, M Krueger, R Jautelat US Patent 7,338,958, 2008 | 89 | 2008 |
| CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents U Lücking, M Kruger, R Jautelat, O Prien, G Siemeister, A Ernst US Patent 7,288,547, 2007 | 83 | 2007 |
| The kinase chemogenomic set (KCGS): an open science resource for kinase vulnerability identification CI Wells, H Al-Ali, DM Andrews, CRM Asquith, AD Axtman, I Dikic, ... International journal of molecular sciences 22 (2), 566, 2021 | 79 | 2021 |
| A New, Practical One‐Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides F Izzo, M Schäfer, R Stockman, U Lücking Chemistry–A European Journal 23 (60), 15189-15193, 2017 | 79 | 2017 |
| Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709 G Siemeister, U Luecking, C Wagner, K Detjen, C Mc Coy, K Bosslet Biomedicine & pharmacotherapy 60 (6), 269-272, 2006 | 75 | 2006 |
